PREDNISONE TABLETS

Stage IV Bladder Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Stage IV Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
TRASTUZUMAB Iambic Therapeutics, Inc	Phase 2	BB
Carboplatin Iambic Therapeutics, Inc	Phase 2	BB
Inno-206 M.D. Anderson Cancer Center	Phase 2	B
Cediranib National Cancer Institute (NCI)	Phase 2	B
Sorafenib National Cancer Institute (NCI)	Phase 2	B

View all 16 →

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant

BBB

Indicative ·

76 / 100

diffuse large B-cell lymphomaDormant

BBB

Indicative ·

74 / 100

metastatic prostate carcinomaDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.